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of cardiacmortality with reduction of 24-hour HRV was examined in both
Amiodarone and Placebo groups.
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The results (Figures: full line = arrhyfhmic mortality, dashed line = non-
arrhythmic mortality) show that while inPlacebo group, reduced HRV was
strongly associated with arrhythmicbut not non-arrhythmia mortality, the op-
posite wee true in the Amiodarone treatad group. Thus the study confirms
that also in patients with reduced LVEF,HRV is a strong predietor of arrhyth-
mia mortality. The study further suggests that some patients who would die
an arrttythmic death auffer a non-arrhythmia death when on Amiodarone.
m1078122 Identification and Management of High-RiskPatiente With Acute Mvocerdial Infarction: The
National Regiatry of M~ocardial Infarction
M. Burns, R.C. Becker, J.M. Gore, C. Lambrew, W. French, W. Rogers for
the National Registry of Myocardial Infarction (NRMI-2) Investigators.
Unive~ifyof Massachusetts Medical Schrwl, Worceste6 MA, USA
High stendarda of cost-effective medical care require practical methods for
riakstratifieation and timely appropriation of available treatmenta. The NRMl-
2 Riak Aeseesmant was validated using a database including over 200,0fYJ
patients with myoeardial infarction (Ml). Independent predictors of an adverse
in-hospital outcome were: Killip IV (OR 4.46), systolic BP <100, pulse >100
(OR 2.0) Killip Ill (OR 1.59), age=- 70 yeare (OR 1.42), Killip II (OR 1.41),
STelevation on initial ECG (OR 1.32), anterior site of Ml (OR 1.23) and prior
Ml. (OR,1.10) (all p <0.001 except age p -= 0.01). Thrombolytice (47.5 vs
18.6Y0;p = 0.0001) and either IQ PTCA or emergent CABG (9.3 vs 5.IYo;
p = 0.0001) were utilized more often in the eaffy management of high than
low-risk patients. Door-to-drug (91 versus 62 minutes; p = 0.0001), door-
to-balloon (247 versus 161 minutes; p = 0.0001) and door to bypaas (439
veraus 300 minutes; p = O.OQOI)times were all lower in high-risk patients.
Mortality among high-riak patients receiving thrombolytic tx (n = 26,367) IQ
PTCA/CABG (n = 5,1S1) and thoae without repetiusion (n = 23,973) was
6.1%, 10.3%, and 21.4%, respectively (p = 0.0001). Risk stratifieetlon is
possible using readily available demographic, ECG and clinical information.
The NRMI-2 Risk Assessment Assignment provides insight into health care
trends in the U.S.
H1078123 Vagal Reflexes and Left Ventricular Function inPeat-Mvocardial Infarction Patients: Results
from th~ ATRAMI Study
M.T. La Revere, A. Mottara, S.H. Hohnloaer, J.T. Bigger, Jr., F.1.Marcus,
R. Nohara, P.J.Schwartz for the ATRAMI Investigators. “S. Maugeri”
Foundation, /RCCS, Montesceno Pavia, Italy Universifyof Pavia, Italy
Unequivocal data have shown that Baroreflex Sensitivity (BRS) is depressad
in post myoeardial infarction patienta but whenever is logical to assume
that the larger the infarct size the lower the baroreceptore’ response, the
relationship between the autonomic derangement and ventricular function
has not been fully elucidated. in the ATRAMI (Autonomic Toneand Reflexes
After Myocardial Infarction) study 1176 out of 1264 patienta had both BRS
(phenylephtfne method) and LVEF (Echo, Angio or MUGA) (mean BRS 7.2
+4.9 mdmmHg, LVEF49 *2%) measured within one week. The correlation
between BRS and LVEF,as well as between BRS and CPK Ievela(n = 1026)
was weak (respactivaly, r = 0.17 and r = 0.06). However, when LVEF was
categorizedin 3 groups (S 35, 3e-50, > 50%), a more depressed BRS was
detected in the lowest LVEF group (4.9+ 3.8 vs 7.4 + 4.6 and vs 7.7 +5,
both p -=0.001) and the number of patients with a markedly depressed BRS
(<3 ma/mmHg) was significantly highar among patients with reduced LVEF
as compared to patients with LVEF 36-50% and > 50% (34% vs 14% and
11% ~5@ively, p < o.01). In the ATRAMI study survival analysis showed
the depraeead BRS (-=3 me/mmHg) and reduced LVEF (S 35%) were both
independent predictors d survival (Muitivariate RR 2.8 (95Y0Cl 1.2-6.1) for
BRS and RR 4.7 (95% Cl 2.0-10.8) for LVEF). Moreover the presence of
both depressed LVEF and BRS significantly increaaad the RR to 13.4 (95%
Cl 6.6-27.4).
Conclusion: In poet-Ml patients baroreflex activity is weakly related to
the extent of ventricular damage as measured by LVEF. Both indexes of
ventricular and autonomic dyafunetion are independently associated with a
poor prognosis and the combination of BRS and LVEF is of meaningful value
in the identification of patients at increased risk for cardiac mortality.
I1078-124I kI-ho5PitalAdverse Cardiac Eventa Following
First Myocardial Infarction Ara Similar Among
African-Americans and Caucasian
F. Khaja, H.N. Sebbah, M. Alam, G. Divine, S. Borzak, S. Smith,
K.G. Richer-Cornish, S. Goldstein. Henry Ford lfeartand Vaacu/ar/rrstitute,
Detroit, Ml, USA
Itiegenerally believed that African-Americans (AA) experience greater ad-
verse cardiacevents following an acute myocardial infarction (AMI) compared
to Caucasians (C). In the present study, we prospeefively examined the in-
hospital adverse cardiac events in a cohort of 392 consecutive patients (125
AA and 267 C) with a firet AMI admitted to the cardiac intensive care unit
during a period of 4 yeare. A patient was considered to have had an advarae
cardiac event if one of the following occurred during the index hospitalization:
death, ventricular fibrillation (VF) or ventricular tachycardia (VT), pulmonary
congestion (PC) orcardiogenic shock (CS), reinfaretion (Rl) or post-infarction
angina (PIA).
AA c Relative Risk and P-value
(%) (%) 950/.Confldsncs Intervsl
Death 6 3 1.42 (0.52, 3.91) 0.49
VF or VT s 10 0.79 (0.40, 1.5s) 0.51
PC or SC 21 20 1,03 (0,6S, 1,56) 0.90
RI or PIA 22 20 1,13 (0.75, 1.69) 0.56
Any Event 37 42 0.s7 (0.66, 1.14) 0.30
The data indicate that, following first AMI, in-hospital adverae events are
not statistically different between AA and C. This lack of difference between
races is maintained even after adjusting forage and gender (Cox regression).
We conclude that AA experience similar rates of in-hospital adverse cardiac
events after a first AMI as C.
1078-125 Chlamidia Pneumonia Infection and
Atherosclerotic Coronary Disease
M. Pence, R. Sessa, M. Di Pietro, A. Vatveri, G. Aurigemma, F. Fadele,
M. Del Piano, A. Dagianti. Department of Cardiovaecu/ar and Ffespiratory
Sciences and Department of Microbiology, La Sapienza fJniverai& Rome,
Italy
Objectives: The aim of this study was to asaess the incidence of Chlamidia
pneumonia antibodies in patients with angiographically verified atheroscle-
rotic coronaryartery disease (CAD). Methods: 114consecutive patients were
investigated between April 1994 and June 1995. Patients ware divided into
two groups: one of 72 patients with acute myocardial infarction (AMI) (53
men, 19 women, mean age 62.57 + 10.12), the other of 42 patients with
chronic ischemic heart disease (37 men, 5 women, mean age 62.75+ 9.26).
Identification of Chlamidia pneumonia was cerriad out with the micro im-
munofluorescence method (Alifax), on serum samples taken from patients
on the day after admission to the hospital. The lgG and lgA anti-Chlamidia
pneumonia titre was assessed, values> 1.32 and> 1:8 being respectively
considered significant. Resu/ts.’outof72 patients with AMI, 67.9% and 37.7%
of the 53 men had a significantly high lgG and lgAtitre respectively; out of 19
women 31% and 15.8%had a significantly high lgG and lgAtitre respectively.
Out of 42 patients with chronic ischemic haarl disease, 45.9Y0and 35% of
the 37 men had a significantly high lgG and lgA titre respectively; only one
woman out of 5 had a high lgG and lgA titre. Conclusion: These date show
that after AMI, in a high percentage of patients there is an abnormally high
antibody lgG and lgA titre, the former being more significant. A high antibody
titre in a smaller percentage of patients in the group with chronic ischemic
heart disease suggests that there may be an exacerbation of Chlamidia
pneumonia infection during AMI, but these data do not provide evidence of
a direct linkand aclear relationship between Chlamidia pneumonia infeetion
and clinical symptoms of atherosclerotic coronary disease.
~ DeterminantsofLongTerm Cardiovascular Drug
Uae After Myocardial Infarction: Does Country
Make a Difference?
A.M. Ross, J.S. Reiner, K.S. Coyne, Y.C. Draoui, C.F. Lundergan. The
Gaorge Washington University Washington, DC, USA
International clinical trials have uncovered substantial differences in adjunc-
tive treatments post myoeardial infarction (Ml) between countries despite
rapid information axchange between continents. We examined 2 year follow-
up data from 1S46 patients in the GUSTO-1 angiographic study to identify
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determinants of poet Ml cardiovascular drug use including nationality. Sig-
nificant differences exiatad between patient groups treated within the United
States (US) and other nations (NUS) (Europe, Canada&Australia). The US
group had a greater proportion of females, hypertensive (HTN), diabetica
and patients with prior bypass surgery (all p c 0.002). No differeneas wera
notad in age, time to treatment, recurrent ischemia or ra-infarction (all p >
0.05). The last ESVI before hospital discharge was significantly smaller in
US patienta compared to NUS (p -=0.0001). Multivariable analysis identified
determinants of long term cardiovascular drug use listad below according to
rank. (p value).
ACE Calcium Blwcker Bets Blocker Vasodilators
tESVl (0.0001) HTN (0.0001) NUS (0.0001) NUS
HTN (0.0001) us (0.0002) NoCHF (0.0001) Smoker (0.09)
CHF (0.0001) JESVI (0.02) HTN (0.002) Female (0,01)
NUS (0.0001) NoCHF (0.03) Age <75 (0.002) -
Diabetee (0.001) Smoker (0.03) ~Lipids (0.05) -
Female (0.01) - $ESVI (0.009) -
Conclusions.’ 1). Long term post Ml drug use is in pari dependent on
nation specific practice patterns after correction for specific drug indications.
2). US patients are less likely to receive ACE inhibitors or bate blockers than
NUS patients post Ml. The etiology of these differences is unknown. The
‘global community” is not yet a madicsl reality regarding post Ml medical
therapy.
m1078127 T WavaChangeaAftarReperfuesdAcuteMyocardialinfarction:A Markerof infarctSiza
T. Onodera, A. Takizawa, M.-S. Kim, H. Fukita, A. Uehara, T. Urushida,
T. Yonada, S. Miyamaoto, M. Matsunaga, T. Kubota. S/rizuo/raCify M.spita/,
Shizuoka, Japan
Implication of asymptomatic pracordial T wave changes after anterior acute
myocardial infarction (AMI) were evaluated in 84 patients who receivedemer-
gent angiography with reparfusion therapy. ECG recordings were obtained
tiicea day for a week. Patients were divided into those without Twave inver-
sion after reperfusion therapy, those who showad normalization of invertad
T wave in convalescent phase of AMI and those without normalization of
invertad T wave. Left ventricular ejection fraction (LVEF), % systolic short-
ening of infarct-related segment (%SS), left ventricular end-diastolic volume
index (EDVI) and patency of the infarct-related artery were evaluated in
angiography’on admission and at 1 month of AMi.
T wave inversion was noted in 74 of 84 patients. Normalization of invertad
T wave was seen in 49 of the 74 patienta at 82 + 32 hours after onset of AMI.
T inversion(–) T normalization(+) T normalization(–)
peak CK (lUil) 6846+ 3765* 4754 &2547# 2123+ 1031
On admission
LVEF (%) 40+5” 44 +9# 55* 16
%ss -1,6+ 1.9$ 6.1 &6.9# 13.1 * 10.1
EDVI 101 * 11” 92& 16 84*2O
1 monthafter AMI
LVEF (%) 38& 9* 46* 13# 56 k 14
%ss 2.7& 5.9* 10.4+ 8,ti 19.2 + 6.6
EDVI 129 + 20” 92& 17 65& 16
Coronaty reoeclueion 2/10 (20%) 5/49 (lo%) 4/25 (16%)
*p< 0.05 veothers, #p < 0.05va T nOrmalizstiOn(–)
Thus, absence of T wave invereion after reperfusion therapy was as-
sociated with the largest infarction. Infarction waa larger in patients with
normalization of invertad T wave than in thoae without normalization. T wave
changes were not associated with coronary raoeelusiort.UprightTwave may
l“
be a sign of left ventricular remodeling or profounder myoeardial damage.
D 1078-128 lathe ECGAdequateto idantifyPatientsWithLeftCircumflexOccluaioninAcuteCoronary
Syndromes?
P.B.Amsterdam, G.E. Hafley, R.A. Barrington, C.B. Granger, E.J. Topol,
o R.M. Califf for the GUSTO-llb Investigators. Duke University Msdica/
,
Centec Durham, NC, USA
Studies of acute coronary syndromes (ACS) have shown that STelevation is
highly specific, but less sensitive, for total coronaty oeelusions,particularly of
l the left circumflex (LCX). To further investigate the ECG characteristics and
o outcomes of acute LCXoeelusions, weetudiad patients inthe GUSTO-llbtrial
(of heperin vs. desirudin in ACS) with enzymatic evidence of Ml at enrollment
and the LCX identified astheculpritartery ateardiaceetheterization. Of these,
250 had evidence of LCX occlusion based on ST elevation at presentation,
.
and 1S0 had no ST elevation but LCX occlusion based on 100% stenosis
and/or TIMI c 2 flow. Thus, 41.9% of patients with LCX occlusion and Ml had
no ST elevation. Outcomes for these patiente are shown (table).
n Death at 30 deye, Peek CK-MS, Killipz Ill, LytiesJIQPTCA,
n n (“A) lull n (OA) n (“/.)
ST+ 250 1 (0.4)” not 12 (4.6) 224 (90)
No’ST? 160 8 i4.4i* 71t 15 i6.3i 33 (;6.3)
*p= 0.004;t p = 0.0003
Conclusion: Absence of ST elevation in Ml due to LCX occlusion is
ebmmon. Mortality was significantly higherat30 days in the non-ST-elevation
group, perhape because fewer got reperfusion therapy despite occluded
culprit arteries. More sensitive, noninvasive ways to identify LCX occlusion
(than the 12-lead ECG) should be developad to determine whether these
patients, if identified early, would benefit from repatiusion therapy.
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D1079110 A 8eiectiveUeeofTissuePlaeminogenActivator
and8treptokinasefor AcuteMyocardiai
infarctioniaMoreCoat-affectiveThanthe
ExclusiveUeeofTissuePlasminogenActivator
R. Lorenzoni, G. Fattore, G. Gensini. Inst. of Cwdio/ogy, Universifyof
F/orenceand Bocconi Univerei~ Milan, Italy
Thrombolysis in acute myocardial infarction (AMI) with tissue plasminogen
activator (tPA) is eoet-effactive in respect to the use of streptokineee (SK).
Aim of this refxxl istotest the cost-effectiveness of aseleetive use of SKand
tPA for the treatment of AMI. Methods: We testad two alternative protocols.
Protoco/ A: tPA in patients agad c 75 yeare, SK in patients aged z 75
yeare. Protoco/B:tPA in patienta with anterior AMI, SK in patients with other
AMI. The mats for the two thrombolytic strategies are those repotted for
GUSTO trial: tPA 2.216 and SK 270 US $/treatment; no additional coats
were Computed.Thirly-day mortality ratee and distribution in subgroups (in
brackets after each subgroup) are those repotied in the GUSTO trial: tPA
6.3% and SK 7.3% for the general population; tPA 4.4% in patients agad <
75 yeare (88Y.), SK 20.6% in patients agad ? 75 years (12%); tPA 8.6% in
patients with anterior AMI (39%), SK 5.3% in patients with other AMI (61%).
Resu/te.’Data are for 1.000 patients treated and rests are expressad in US
$. The exclusive use of SK costs 270.000 with 73 deaths. Costs, deaths,
and costs for each extra life saved with the exclusive use of tPA and the
use of protocol A and B in respect to the exclusive use of SK, are shown in
tabie.
costs Deaths Cost/lifesaved
tPA 2,216,000 63 t94,600
ProtocolA 1,962,480 64 190,276
ProtocolB i.02s.e40 65 e4.s67
Therefore, the cost of each extra life saved (2 life saved every 1.000
patients treatad) with the exclusive use of tPA inetead of the use of protccol
B would be 593.530. Conclusions: The use of tPA in anterior AMI and SK in
other AMI could be more cost-effective than the exclusive uae of tPA.
W1’ThrombinGeneration~urin9Thr m~oiYaiawi~~
rt-PAandConjunctiveTherapyWithr-Hirudinin
PatientsWithAcuteMyocardiaiInfarction
U. Zeymer, M. Mateblowski, K.-L. Neuhaus. SWffische K/iniken Kaase/,
Germany
Thrombolytic therapy is known to induce not only Iysis of thrombi but also
proeoagulant effects. Thrombin is one of the most important factors invoivad
in the pethogenesis of acute corona~ syndromes. We determined thrombin
generation in 17 patients with acute myoeardial infarction before, during and
after thrombolyeis with front-loaded rt-PA (100 m@O rein) and conjunctive
therapy with raeombinant hirudin (HBW 023; bolus of 0.4 mg/kg, infusion of
0.15 mg/k@h over 46 houm). Pro-thrombin fragment 1.2 (F1.2), thrombin-
antithrombin Ill complex (TAT) and free r-hirudin plaama levels (Hir) were
determined at baseline (before), during (30 and 80 rein) and after (4 and 24
h) thrombolysis. Mean values+ SD are shown in the table.
